FDA approval covers capsular-bag implantation for adult aphakia correction with <1.0 D corneal astigmatism; a toric PureSee Toric II option targets ≥1.0 D astigmatism. Pivotal US randomized, masked, ...

FDA has approved Johnson & Johnson's Tecnis PureSee IOL, an extended depth of focus (EDOF) intraocular lens (IOL) intended for use in cataract surgery. The new IOL will be available to U.S. patients ...

A team of researchers at the University of California, Los Angeles (UCLA) has introduced a novel framework for monitoring structural vibrations using diffractive optical processors. This new ...

Milestone includes more than 6 million PCIOL implants worldwide, with PanOptix and Vivity leading globally in trifocal and EDOF IOLs1,* PanOptix delivers outstanding patient satisfaction and freedom ...

GENEVA--(BUSINESS WIRE)--Alcon, the global leader in eye care dedicated to helping people see brilliantly, today proudly announced that more than 175 million of its intraocular lenses (IOLs) have been ...

Background/aims To assess binocular visual performance, visual acuity at different contrast levels and visual disturbances in patients with primary open-angle glaucoma (POAG) undergoing bilateral ...

ABSTRACT: The demand for full-range visual quality in refractive cataract surgery has driven the development of non-diffractive extended depth of focus (EDOF) intraocular lenses (IOLs). Vivity ...

Each year, more than 30 million people globally receive surgery to correct cataracts. As many people age, the crystalline lenses in their eyes become cloudy and obstruct their vision, but a simple and ...

“Reaching the one million milestone for Vivity, the world's leading EDOF IOL, represents a meaningful achievement in restoring distance, intermediate and functional near vision for people worldwide, ...

Please provide your email address to receive an email when new articles are posted on . In the U.S. market, we currently have three newer multifocal IOLs approved for use: the Alcon Clareon PanOptix ...